Abstract

The purpose of this 12-week open label, non-randomized, single center study was to evaluate the effects of a novel multivitamin antioxidant (MV-ONE) on end stage renal disease (ESRD) patients that require consistent treatment for secondary hyperparathyroidism and anemia. However, further multicenter studies with larger patient populations are required to validate results.

Results

1. MV-ONE Therapy Significantly Increases Vitamin D Levels in Hemodialysis Subjects

   A) 25-OH Vitamin D levels
   B) Vitamin D (Supplementation)

2. MV-ONE Therapy Significantly Decreases The Epogen Dosing Required In Hemodialysis Subjects

   A) Epogen Dosing
   B) Transferrin Saturation

3. MV-ONE Did Not Alter Uric Acid, C-Reactive Protein Or Cholesterol Levels In Hemodialysis Subjects

   A) Uric Acid Levels
   B) C-Reactive Protein Levels

4. MV-ONE Pharmacoeconomic Advantages (HYPOTHETICAL)

Conclusions

MV-ONE increases active vitamin D blood levels in hemodialysis patients identifying it’s efficacious ability to potentiate treatment for secondary hyperparathyroidism.

MV-ONE decreases the ESA therapy required in hemodialysis patients identifying it’s benefits aiding in the treatment of CKD- and hemodialysis-induced anemia.

Approximately 85% patients reported overall improved well-being after taking MV-ONE. Quality of life questionnaires should be used in future studies.

The antioxidative properties of MV-ONE therapy may be a useful cost-effective adjunct in an increasingly challenging clinical environment.

Materials and Methods

An open label, non-blinded, non-randomized single site study lasting 12 weeks (excluding screening and baseline laboratory periods). Multiple laboratory parameters were compared to controls.

End stage renal disease and on hemodialysis for 90 days prior to screening.

Cholecalciferol

End stage renal disease and on hemodialysis for 90 days prior to screening.

Vitamin D dose and transferrin saturation.

MV-ONE therapy. The 12 week administration of the novel renal multivitamin antioxidant

Figure 1. A) The 12 week administration of the novel renal multivitamin antioxidant

Figure 4. The costs of

MV-ONE therapy. The system wide hemodialysis population was estimated as 3000 with 75% on ESA therapy. Patient compliance was estimated to be 80%.